Amphetamine Sulfate NDC 72162-1613

NDC codes

FDA NDC Directory

Product NDC (as listed)72162-1613Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72162-1613Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72162-1613-3	72162161303	30 TABLET in 1 BOTTLE (72162-1613-3)Marketed from Mar 29, 2018

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Amphetamine Sulfate
Generic name (nonproprietary): amphetamine sulfate
Active ingredients: Amphetamine sulfate — 10 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 200166
Marketing start: Mar 29, 2018
Listing expires: Dec 31, 2027
DEA schedule: CII
Other FDA classes: Central Nervous System Stimulation (Physiologic effect)
Identifiers: Product ID 72162-1613_a4979cf8-6c66-4c04-ad25-bc4dfefa80daSPL ID a4979cf8-6c66-4c04-ad25-bc4dfefa80daSPL set ID b94e2562-fd19-455f-ac10-2cc24302d27aRxCUI 1600695UNII 6DPV8NK46S
Pharmacologic class: Central Nervous System Stimulant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472162161303 followed by a unit qualifier and the quantity

Package 72162-1613-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 30, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Amphetamine Sulfate Tablets, USP, are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disabil…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 200166

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 200166
Product	Strength	Form · route	Labeler	Product NDC
Evekeoamphetamine sulfate	Amphetamine sulfate 5 mg/1	TabletOral	Azurity Pharmaceuticals, Inc.	24338-022
Evekeoamphetamine sulfate	Amphetamine sulfate 10 mg/1	TabletOral	Azurity Pharmaceuticals, Inc.	24338-026
Amphetamine Sulfate	Amphetamine sulfate 5 mg/1	TabletOral	Bryant Ranch Prepack	72162-1612
Amphetamine Sulfate	Amphetamine sulfate 10 mg/1	TabletOral	Bryant Ranch Prepack	63629-2498
Amphetamine Sulfate	Amphetamine sulfate 5 mg/1	TabletOral	Wilshire Pharmaceuticals, Inc.	52536-057
Amphetamine Sulfate	Amphetamine sulfate 5 mg/1	TabletOral	Bryant Ranch Prepack	63629-2499
Amphetamine Sulfate	Amphetamine sulfate 10 mg/1	TabletOral	Wilshire Pharmaceuticals, Inc.	52536-059